Robert A Anders
Overview
Explore the profile of Robert A Anders including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
205
Citations
31945
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Argani P, Oshima K, Anders R, Gonzalez R, Yilmaz O, Bal M, et al.
Am J Surg Pathol
. 2025 Jan;
PMID: 39815455
The cholangioblastic variant of intrahepatic cholangiocarcinoma is a distinctive neoplasm that typically affects young women without underlying liver disease. Morphologically, it demonstrates solid, trabecular, and tubulocystic architecture, biphasic small cell-large...
2.
Montagne J, Mitchell J, Tandurella J, Christenson E, Danilova L, Deshpande A, et al.
iScience
. 2025 Jan;
28(1):111569.
PMID: 39811671
Successful pancreatic ductal adenocarcinoma (PDAC) immunotherapy requires therapeutic combinations that induce quality T cells. Tumor microenvironment (TME) analysis following therapeutic interventions can identify response mechanisms, informing design of effective combinations....
3.
McMiller T, Besharati S, Yarchoan M, Zhu Q, Unsal-Kacmaz K, Xu K, et al.
J Immunother Cancer
. 2024 Nov;
12(11.
PMID: 39572160
Background: Gastric carcinomas (GC) are aggressive malignancies, and only ~15% of patients respond to anti-programmed cell death (ligand) 1 (PD-(L)1) monotherapy. However, Epstein-Barr virus (EBV)-associated GCs (~5-10% of GCs) often...
4.
Surwase S, Zhou X, Luly K, Zhu Q, Anders R, Green J, et al.
Lab Invest
. 2024 Nov;
105(1):102165.
PMID: 39490742
Spatial proteomics profiling is an emerging set of technologies that has the potential to elucidate the cell types, interactions, and molecular signatures that make up complex tissue microenvironments, with applications...
5.
Deutsch J, Wang D, Chen K, Cimino-Mathews A, Thompson E, Jedrych J, et al.
Lab Invest
. 2024 Oct;
105(1):102166.
PMID: 39461426
Pathologic response is an endpoint in many ongoing clinical trials for neoadjuvant regimens, including immune checkpoint blockade and chemotherapy. Whole-slide scanning of glass slides generates high-resolution digital images and allows...
6.
Shu D, Ho W, Kagohara L, Girgis A, Shin S, Danilova L, et al.
Nat Immunol
. 2024 Oct;
25(11):2110-2123.
PMID: 39455893
Tertiary lymphoid structures (TLS) are associated with improved response in solid tumors treated with immune checkpoint blockade, but understanding of the prognostic and predictive value of TLS and the circumstances...
7.
Sidiropoulos D, Shin S, Wetzel M, Girgis A, Bergman D, Danilova L, et al.
bioRxiv
. 2024 Oct;
PMID: 39386736
Graphical Abstract: Highlights: Integrated multi-modal spatial profiling of human PDAC tumors from neoadjuvant immunotherapy clinical trials reveal diverse spatial niches enriched in TLS.TLS maturity is influenced by tumor location and...
8.
Zhang L, Maalouf A, Makri S, Banerjee J, Suru A, Tam A, et al.
Clin Cancer Res
. 2024 Sep;
30(23):5459-5472.
PMID: 39321200
Purpose: Malignant peripheral nerve sheath tumors (MPNST) are aggressive soft-tissue sarcomas and the leading cause of mortality in individuals with neurofibromatosis type 1 (NF1). Despite many clinical trials, outcomes for...
9.
Ishida C, Myers S, Kubota C, Shao W, McGuire M, Liu C, et al.
Cancer Res Commun
. 2024 Sep;
4(9):2539-2552.
PMID: 39240063
Significance: Our findings demonstrate that SREBP pathway activation is a critical part of the metabolic reprogramming that occurs in PDAC development and progression. Therefore, targeting the SREBP pathway has significant...
10.
Nakazawa M, Fang M, Vong T, Zorzi J, Griffith P, Anders R, et al.
Cancer Res Commun
. 2024 Aug;
4(8):2123-2132.
PMID: 39142659
Significance: Surgical resection for localized HCC is typically only reserved for those with solitary tumors without vascular invasion. In this retrospective analysis, we show that neoadjuvant immunotherapy may allow high-risk...